

Revised HOME-CoV - Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department.

Head :Douillet Delphine

Last update : 05/05/2021 | Version : 1 | ID : 73909

General

Identification

Detailed name	Study on the implementation of the revised HOME-CoV score to guide the choice of hospitalisation or outpatient management of patients with confirmed or probable SARS-CoV-2 infection admitted to an emergency department.
---------------	--

Sign or acronym	Revised HOME-CoV
-----------------	------------------

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	2020-A03067-32
--	----------------

General Aspects

Medical area	Emergency medicine
--------------	--------------------

Study in connection with Covid-19	Yes
-----------------------------------	-----

Health determinants	Healthcare system and access to health care services
---------------------	--

Scientific investigator(s) (Contact)

Name of the director	Douillet
----------------------	----------

Surname	Delphine
---------	----------

Address	Departement de Médecine d'Urgence 4 rue Larrey CHU ANGERS
---------	---

Email	Delphine.Douillet@chu-angers.fr
-------	---------------------------------

Collaborations

Funding	
Funding status	Public
Details	Angers University Hospital
Governance of the database	
Sponsor(s) or organisation(s) responsible	Angers University Hospital
Organisation status	
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Cohort study
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	Yes
Details	Performed at group level (clusters)
Database objective	
Main objective	<p>The primary objective is to demonstrate the reliability and safety of outpatient management among patients highly suspected or confirmed as infected with COVID-19, attending an emergency department and with a revised HOME-CoV score less than 2 (negative rule).</p> <p>The secondary objectives are as follows:</p> <ul style="list-style-type: none"> i. Evaluate the rate of patients having required hospitalisation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule. ii. Evaluate the rate of patients having required hospitalisation and initiation of oxygen therapy within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.

- iii. Evaluate the rate of patients having required intubation within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- iv. Evaluate the rate of all-cause deaths within 7 days following inclusion according to the revised positive or negative HOME-CoV rule.
- v. Evaluate the performance of the revised HOME-CoV score in predicting a negative outcome in the patient subgroup with SARS-CoV-2 infection confirmed by RT-PCR to rule out the risk of a negative outcome when assessed as low risk.
- vi. Compare the performance of the revised HOME-CoV score with that of other existing scores.

Inclusion criteria	<p>Adult patient (> 18 years),</p> <ul style="list-style-type: none"> - Attending one of the emergency departments taking part in the study due to COVID-19 infection confirmed by SARS-CoV-2 positive RT-PCR, or considered highly probable by the physician managing the patient, - Not requiring management in a continuous care or intensive care unit, and subject to a decision to limit active treatment, - Having given their formal consent to take part in the study, - Registered with or a beneficiary of a social security scheme.
Population type	
Age	<p>Adulthood (19 to 24 years)</p> <p>Adulthood (25 to 44 years)</p> <p>Adulthood (45 to 64 years)</p> <p>Elderly (65 to 79 years)</p> <p>Great age (80 years and more)</p>
Population covered	Sick population
Pathology	B33 - Other viral diseases, not elsewhere classified
Gender	<p>Male</p> <p>Woman</p>
Geography area	International
Detail of the geography area	France Belgium
Data collection	
Dates	

Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1,300 patients
Data	
Database activity	Current data collection
Type of data collected	Clinical data Declarative data Paraclinical data Biological data Administrative data
Clinical data (detail)	Direct physical measures Medical registration
Declarative data (detail)	Face to face interview
Procedures	
Followed pathology	
Promotion and access	
Promotion	
Access	